Danaher Corporation $DHR Shares Acquired by Park National Corp OH

Park National Corp OH lifted its holdings in Danaher Corporation (NYSE:DHR) by 6.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 90,107 shares of the conglomerate’s stock after purchasing an additional 5,678 shares during the period. Park National Corp OH’s holdings in Danaher were worth $18,187,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DHR. BlackRock Inc. acquired a new stake in Danaher in the 2nd quarter valued at about $10,492,520,000. Jupiter Topco LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher in the second quarter valued at approximately $1,287,949,000. Bank of America Corp DE acquired a new stake in shares of Danaher in the second quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc purchased a new position in Danaher during the second quarter worth approximately $801,056,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 2.3%

DHR traded up $4.92 on Monday, hitting $218.98. The company had a trading volume of 761,506 shares, compared to its average volume of 4,454,343. The company’s fifty day moving average price is $209.20 and its 200 day moving average price is $193.70. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm has a market cap of $153.94 billion, a P/E ratio of 38.91, a PEG ratio of 2.67 and a beta of 0.76.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period last year, the business earned $0.77 earnings per share. As a group, equities analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Piper Sandler began coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 target price for the company. The Goldman Sachs Group boosted their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. UBS Group initiated coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. Guggenheim lifted their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Evercore reiterated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $234.09.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.